Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2011, the first quarter of fiscal 2012. The filing was signed November 14, 2011. Palatin is a development-stage biopharmaceutical company; its lead candidate, bremelanotide for female sexual dysfunction, was in Phase 2B trials.
Financial results and liquidity
| Metric | Quarter ended Sep. 30, 2011 | Quarter ended Sep. 30, 2010 |
|---|---|---|
| Revenue | $27,217 | $216,147 |
| Research and development | $2.284 million | $3.453 million |
| General and administrative | $1.109 million | $1.382 million |
| Operating loss | $3.367 million | $4.618 million |
| Net loss | $3.354 million | $4.600 million |
| Basic and diluted loss per share | $0.10 | $0.39 |
| Operating cash used | $3.976 million | $4.211 million |
- All reported revenue came from AstraZeneca-sponsored research agreements and represented reimbursement of development costs and employee compensation. Revenue fell about 87% year over year.
- R&D expense declined about 34% and G&A expense about 20%, primarily reflecting staffing reductions and a narrowed development focus. Net loss narrowed about 27%. The lower per-share loss also reflects a higher weighted-average share count: 34.9 million versus 11.7 million.
- Cash and cash equivalents were $14.884 million at September 30, down from $18.870 million at June 30, 2011. Operating activities used $3.976 million; financing activities used $10,256, principally for capital-lease payments. Investing cash flow was zero.
- Current assets were $15.287 million and current liabilities $1.657 million. Total liabilities were $1.795 million. The filing reports capital-lease obligations of approximately $66,853 in total; it does not report conventional borrowings.
- There is no meaningful operating margin disclosure for this development-stage company; revenue was minimal relative to operating expenses. Accumulated deficit was $225.345 million.
Business developments, outlook, and risks
- Management planned to concentrate available resources on the ongoing bremelanotide Phase 2B trial, with limited work on PL-3994, an inhaled candidate for acute asthma that remained in preclinical research. AstraZeneca’s AZD2820 obesity candidate was in Phase 1.
- Management said existing capital was expected to fund planned operations, including the bremelanotide Phase 2B trial, through at least calendar 2012. A Phase 3 bremelanotide program would not begin before calendar 2013 and would require significant additional capital.
- The company expected significant losses for fiscal 2012 and additional losses for at least the next few years. It intended to seek funding through collaborations, equity or debt financing, or other sources. Funding may not be available on acceptable terms or at all; without it, Palatin could delay, curtail, partner, or relinquish programs.
- Palatin said it would not substantially fund PL-3994 or other candidate development without additional capital and had ceased research and development efforts on new product candidates. Results depend on clinical and preclinical progress, regulatory approvals, manufacturing, intellectual property, collaboration arrangements, and access to capital.
- Revenue was entirely dependent on AstraZeneca in both comparable quarters. The filing also notes that substantially all cash equivalents were held in one money-market fund sponsored by a large financial institution.
- No material changes to previously disclosed risk factors were reported, and the company reported no current legal proceedings. Management concluded disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
- The filing lists an October 7, 2011 letter agreement with Biotechnology Value Fund, L.P., but its terms are not provided in the filing text summarized here.
Important facts for investors to verify
- Progress, safety, efficacy, timing, and remaining cost of the bremelanotide Phase 2B trial, and the milestones required before Phase 3.
- Cash runway under actual spending and whether management can secure funding for Phase 3 or other programs before resources are depleted.
- The terms and potential effects of the October 7, 2011 Biotechnology Value Fund letter agreement, including any financing, ownership, or governance implications.
- Future AstraZeneca-related payments, milestones, royalties, and the extent to which Palatin remains dependent on that collaboration for revenue.
- Potential dilution: the filing excluded 27.1 million potential shares from diluted loss per share as anti-dilutive, compared with 2.6 million in the prior-year period.